[norbornan-2-yl]methanol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [norbornan-2-yl]methanol
• 英文别名: [(1R,4S)-2-bicyclo[2.2.1]heptanyl]methanol
• 化学式: C₈H₁₄O
• mdl: MFCD00074722
• 分子量: 126.199
• InChiKey: LWHKUVOYICRGGR-KJFJCRTCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [norbornan-2-yl]methanol 在 三乙烯二胺 、 偶氮二甲酸二异丙酯 、 potassium carbonate 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 92.0h， 生成 2-chloro-6-[3-[[norbornan-2-yl]methoxy]pyrazol-1-yl]pyridine-3-carboxylic acid
  参考文献：
  名称：

  [EN] MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
  [FR] MODULATEUR DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE, COMPOSITIONS PHARMACEUTIQUES, PROCÉDÉS DE TRAITEMENT ET PROCÉDÉ DE FABRICATION DU MODULATEUR

  摘要：

  公开号：

  WO2018064632A8

文献信息

• Synthesis and Plasticization Performance of Reactive Plasticizers Utilizing Catalyst-Free Azide-Alkyne Click Reaction
  作者：Yechen Shen、Younghwan Kwon

  DOI：10.1166/jnn.2019.15920

  日期：2019.2.1

  Three different reactive plasticizers (RPs), such as bicyclo[2.2.1]heptan-2-yl-methyl propiolate (NPA), bicyclo[2.2.1]heptan-2-yl-methyl butynoate (NBA), and bicyclo[2.2.1]heptan-2-yl-methyl pent-4-ynoate (NPEA), were synthesized in good yield and characterized. Thermal studies revealed that RPs had low glass transition temperature (Tg < -90 °C) and were thermally stable up to 210 °C. The plasticization

  三种不同的反应性增塑剂（RP），例如双环[2.2.1]庚-2-基甲基丙酸酯（NPA），双环[2.2.1]庚-2-基甲基丁酸酯（NBA）和双环[2.2 .1]庚烷-2-基-戊基4-戊酸酯（NPEA）以高收率合成并表征。热学研究表明，RPs的玻璃化转变温度低（Tg <-90°C），在高达210°C的温度下仍具有热稳定性。根据混溶性，粘度降低和叠氮化物-炔炔Click反应性评估了RPs对GAP预聚物的增塑性能。结果使它们成为基于GAP的聚合物的RP的良好候选。
• [EN] NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE<br/>[FR] NOUVEAUX COMPOSÉS DE SULFAMATE POUR UNE UTILISATION MÉDICALE
  申请人：SOLVAY PHARM GMBH

  公开号：WO2009050252A1

  公开（公告）日：2009-04-23

  This invention relates to sulfamates of Formula (I), wherein R1 to R3 and n are defined in the claims, having carbonic anhydrase enzyme inhibitory activity, to medicaments comprising these compounds, to pharmaceutical compositions comprising these compounds, and to processes for the preparation of these compounds. The invention is also directed to the use of such compounds, medicaments and compositions, particularly to their use in administering them to patients to achieve a therapeutic effect.

  本发明涉及公式（I）的磺酸盐，其中R1至R3和n在权利要求中定义，具有碳酸酐酶酶抑制活性，以及包含这些化合物的药物、包含这些化合物的制药组合物，以及制备这些化合物的方法。本发明还涉及这些化合物、药物和组合物的使用，特别是在将其用于患者治疗以达到治疗效果方面的使用。
• Sulfamate Compounds and Uses Thereof
  申请人：SCHOEN Uwe

  公开号：US20090104126A1

  公开（公告）日：2009-04-23

  A sulfamate compound corresponding to Formula I wherein R1 to R3 and n have defined meanings, pharmaceutical compositions comprising these compounds; a process for preparing these compounds, and the use of such compounds or compositions to treat or inhibit various disorders or disease states in patients in need thereof by administering to such a patient a therapeutically effective amount of such a compound.

  一种对应于式I的磺酰胺化合物，其中R1到R3和n具有定义的含义，包括这些化合物的制药组合物；制备这些化合物的过程，以及通过向这样的患者施用治疗有效量的这种化合物来治疗或抑制患者需要的各种紊乱或疾病状态的使用这种化合物或组合物。
• Substituted arylalkanoic acid derivatives and use thereof
  申请人：Shoda Motoshi

  公开号：US20090062530A1

  公开（公告）日：2009-03-05

  A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C 2 to C 6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

  化合物的化学式为(I)：[在公式中，Link代表具有1至3个碳原子的饱和或不饱和直链烃基，C2到C6在芳环(E)中分别独立地代表环构成碳原子，环构成碳原子中的一个可以被V取代，V代表氮原子或被Zx取代的碳原子，Zx代表具有1至4个碳原子的饱和烷基等，Rs代表-D-Rx等，D代表单键、氧原子等，Rx代表具有3至8个碳原子的饱和烷基等，AR代表部分不饱和或完全不饱和的紧凑双环碳环或杂环，Y代表氢原子、具有1至4个碳原子的低级烷基等]或其盐。提供了具有前列腺素生成抑制作用和白三烯生成抑制作用的化合物。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。